However, the fact that in human AD reduced VGF has been identified as a driver of AD pathology and cognitive decline, and thus as neuroprotective [173], suggests tweaking the C3aR receptor may have therapeutic potential. This evidence concerns the gene VGF and Alzheimer disease.